Objectives: Acute kidney injury (AKI) is a significant risk factor for morbidity and mortality in children. Little is known about community-acquired AKI (CA-AKI) in the pediatric emergency department (PED). Early recognition of AKI allows for nephroprotective measures. The goal of this investigation was to determine the incidence of CA-AKI and the frequency of clinician identified CA-AKI to better inform future nephroprotective interventions.
Global Outcomes [KDIGO] definition) is used to define AKI, 17 the incidence of AKI in hospitalized children is 25%-40%. 8, 10, [16] [17] [18] Little is known about community-acquired AKI (CA-AKI) in children. In scant reports from resource-rich and -poor settings, the incidence of CA-AKI ranges from 0.26% to 1.4%. [19] [20] [21] Unfortunately, the limited data on CA-AKI utilize different definitions of CA-AKI and may not be generalizable to other populations. The incidence of AKI in the pediatric emergency department (PED) remains underinvestigated.
Difficulty in clinical recognition and diagnosis of AKI is highlighted by the discrepancy in epidemiology studies looking at the incidence of hospital-acquired AKI (HA-AKI). A nationwide epidemiologic study used International Classification Diagnosis (ICD-9) codes (a surrogate for clinician recognition of AKI) to identify HA-AKI and found an AKI incidence of only 0.39%, much lower than the 5% to 88% in studies where AKI is determined by investigators using a consensus definition. 22 A second study using diagnosis codes also reported a low HA-AKI incidence of 0.33%. 23 The discrepancy in the investigator-determined and clinician-determined AKI incidence suggests that AKI recognition is inadequate in the clinical setting. All consensus definitions of AKI, including KDIGO, rely on relative changes of serum creatinine from individualized baselines or differing degrees of oliguria. The recognition of CA-AKI is even more difficult in the fast-paced PED, as a baseline creatinine is challenging to determine and reported urine output (UOP) difficult to verify.
Acute kidney injury is not a completely reversible transient phenomenon as long-term sequelae of AKI are seen in up to 70% of children who suffer AKI. [24] [25] [26] [27] [28] [29] [30] Most data on complications of AKI are in hospitalized children; however, studies exist illustrating the longterm sequela of AKI, such as chronic kidney disease (CKD) or death, in outpatients. [28] [29] [30] The severity of complications from CA-AKI is less clear. It is known that early recognition of AKI allows for use of nephroprotective measures such as decreased use of nephrotoxic medications, nephrology consultation, and implementation of strategies that can potentially decrease morbidity and mortality. 27, [31] [32] [33] [34] [35] [36] [37] [38] One successful method of early recognition of AKI is through the use of electronic alerts. 39 Given the unclear burden of AKI among children seen in the ED and the need for early recognition to institute nephroprotective measures, the goal of this investigation was to determine the incidence of CA-AKI in the PED. Secondary aims were to investigate the frequency of clinician identification of CA-AKI, nephrotoxic medication exposure, resource utilization, and patient mortality to better inform future interventions to identify and treat children with AKI at earlier stages.
METHODS
Study Design, Size, Setting, and Participants This was a retrospective cross-sectional study conducted in the PED of a quaternary care, free-standing children's hospital composed of two emergency centers with annual ED volumes of approximately 75,000 (referral hospital) and 45,000 (community hospital), respectively. The community hospital functions as a smaller independent children's hospital with a 26-bed PED, 16-bed intensive care unit, and 25 subspecialty services. Encounters from both PEDs, which serve as referral hospitals for nonpediatric facilities, were included in this study given similar patient populations. The mean hospital admission rate is 16% to 17%, and the hospital cares for a large number of children with chronic comorbid medical conditions predisposing them to AKI. Children 1 month to 18 years of age who were seen in the PED between January 1, 2015, and December 31, 2015, and in whom at least one creatinine level was obtained were included. Children with known CKD and end-stage renal disease (ESRD) were excluded. Patients who died during their PED encounter were also excluded. Some patients had multiple PED visits during the study period; both the number of PED encounters and the number unique patients was evaluated. Institutional review board approval was obtained prior to study initiation and consent was waived. No funding was secured for this research.
Data Sources/Measurement, Bias, and Quantitative Variables Data to be extracted from the laboratory database were determined a priori by the investigators. These data included patient medical record number (MRN), patient encounter number (specific to each PED encounter), age, date, and time of the creatinine collected in the PED, and the creatinine value. A blinded, trained data abstractor (MD) with no conflict of interest, who works as a programmer and senior analyst, probed the hospital laboratory database, extracting PED encounters for patients aged 1 month to <19 years in 2015 with a serum creatinine collected during that PED encounter. In-person meetings and electronic correspondence were used to clarify data elements prior to extraction. Performance of the data abstraction was monitored by one of the investigators (GJB) by verifying code written to extract data and reviewing the data abstracted. If a patient had multiple creatinine levels checked during a PED encounter, the highest creatinine level was used for our study. This data extraction resulted in 15,791 encounters (Data Supplement S1, Figure S1 [available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.com/doi/10. 1111/acem.13421/full]). Subsequently, these data were cross-referenced with a list of all patients who expired in the PED during 2015, removing 19 patients who died that year. The list of PED deaths was maintained independently by the PED service. Our data set was then cross-referenced with a list of patients with CKD and ESRD that was maintained independently by the nephrology service. A total of 286 PED encounters were removed due to the patient having CKD or ESRD. Finally, the KDIGO definition was applied to the 15,486 PED encounters in 2015, resulting in 239 encounters meeting AKI criteria.
Medical records were abstracted for demographics, clinical and laboratory data, resource utilization (admission, use of renal replacement therapy [RRT]), admission unit, comorbidities, medication administration in the PED, hospital length of stay (LOS), and mortality. Race and ethnicity were not included in demographic information as the method of collection and documentation of this data are inaccurate at our hospital. If the patient or family does not complete the race and ethnicity information on the intake forms, PED receptionists document their perception of a child's race/ ethnicity. Potentially nephrotoxic medications were determined a priori by investigators (Data Supplement S2, Table S1 [available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.com/doi/10.1111/acem.13421/ full]). 14, 40 For the 239 encounters, medical record data collection were accomplished by the primary investigator (EOB) with help from an assistant (LM), a trained data abstractor with no conflict of interest, employed by our hospital to solely abstract data for PED-related research. LM was blinded to the hypothesis and outcomes of the study. Twenty practice charts were completed by the trained data abstractor and then reviewed with the primary investigator. The abstractor was then given a standardized abstraction form, an Excel spreadsheet, with only the encounter MRN and date of encounter, and was asked to extract the variables listed above, entering the nominal data in binary format and continuous data in numbers. Ten percent of data were additionally verified by the assistant. Two meetings were held prior to medical record data extraction, one to describe the task and the second to review practice charts and to follow-up on any questions or need for clarification. Using standardized input data documentation, inter-rater reliability for 10% of the data was 97.5%.
Variables
To determine if patients met CA-AKI criteria, the creatinine obtained in the PED during the study period (January 1, 2015-December 31, 2015) was compared to our age-specific reference ranges as baseline creatinine levels. Previous studies imputed different baseline creatinine values when children did not have a personal baseline. 11, 16, 21, 41 As creatinine is reported in ranges, we used the upper cutoff of the age-based range as baseline creatinine. Children were diagnosed with CA-AKI if they had relative or absolute changes in creatinine based on modified KDIGO creatinine criteria (Table 1) . 17 As in other studies, UOP was not used to define AKI given the infrequency with which this is documented in the PED. 10, 11, 42 In addition, the time criterion for the KDIGO AKI definition was not used as this has not been validated in pediatric AKI and is frequently excluded from AKI studies, and we wanted to identify patients with AKI the moment they presented to our PED. <0.3 mL/kg/hr for ≥24 hours or Anuria for ≥12 hours AKI = acute kidney injury; eGFR = estimated glomerular filtration rate; KDIGO = Kidney Disease-Improving Global Outcomes; RRT = renal replacement therapy; UOP = urine output.
10,16
As normal serum creatinine values vary widely with age and muscle mass, our clinical laboratory recently created and validated age and sex-based reference ranges for creatinine using a population study and compared to the Canadian Laboratory Initiative on Paediatric Reference Intervals (Data Supplement S2, Table S2 ). 43 These ranges were placed into the electronic health record (EHR) and flagged when abnormal; however, this study included the time frame preceding that practice change. During the study period, our laboratory identified one wide range of creatinine values as normal for all pediatric patients; creatinine levels did not flag as abnormal until greater than 1.06 mg/dL, regardless of age.
The primary outcome was the frequency of CA-AKI among children seen in the PED. Secondary outcomes included the frequency with which AKI was identified, the proportion of children with AKI in whom potentially nephrotoxic medications were administered, hospital LOS, RRT, and mortality during that hospitalization. Not all outcomes could be evaluated in two children transferred to other hospitals. AKI was considered identified if patients were given ICD-9 code or diagnosis for AKI to include acute renal failure, renal failure, or renal insufficiency. Diagnoses were entered by PED attendings, fellows, and residents. An additional analysis was conducted to evaluate if clinicians had concern for renal function but did not formally diagnose AKI. EHRs were reviewed and considered as showing concern for renal function if the PED note mentioned AKI without formal coding, renal imaging was obtained, or nephrology was consulted. We grouped the patient encounters with a diagnosis of AKI and those encounters with concern for renal function as the "renal conscious" group. We also performed additional analyses using the creatinine flagged as abnormal in the EHR to evaluate if this increased clinician recognition of AKI. Multivariable regression analysis was conducted controlling for sex, age, stage of AKI, and presence of a comorbidity.
Data Analysis
Continuous data were presented as median and interquartile ranges (IQR) and compared using parametric or nonparametric tests as appropriate. Frequencies were described using percentages. Categorical data were compared using the Fisher exact test or Pearson's chi-square test with results in odds ratio (OR) with 95% confidence intervals (CIs). Multivariable analyses were performed using backward stepwise logistic regression and are reported by OR with 95% CIs. Analyses were performed using JMP Statistical Software from SAS (JMP 13, SAS Institute). The difference in population proportions was conducted using an online calculator at vassarstats.net.
RESULTS
Frequency of AKI and Demographics of the Cohort During the study period, 15,486 encounters seen in the ED had a creatinine obtained, representing 13% of the 119,151 visits seen in the ED that year. Community-acquired AKI was present in 239 of 15,486 (1.5%) encounters in which a creatinine was obtained ( Table 2 ). The majority of AKI patient encounters 135 of 239 (57%) were male; the median age was 11 years (IQR = 4-15 years). In 64% (154/239) of encounters, patients had medical comorbidities: cardiac disease (33/ 239, 14%), prior renal disease (not CKD; 32/239, 13%), organ transplantation (30, 13%), endocrinopathies (20, 8%), and oncologic (13, 5%). Thirty-three percent (78/239) of encounters had previous creatinine measurements available in our EHR. Forty-seven percent of encounters had stage 2 or 3 AKI. Most (202/ 239, 85%) patient encounters with AKI resulted in admission. Three patient encounters (two patients) with AKI resulted in transfer to another hospital for admission and their inpatient data (diagnosis rate, LOS, or RRT need) were unknown. Median LOS was 5 days (IQR 2-10 days), higher than our median hospital LOS of 1.8 days for all patients. In 38% (76/199) of encounters, patients needed admission to a critical care unit. Four encounters (four patients) with CA-AKI progressed to need RRT; all four received continuous venovenous hemodialysis for a median duration of 5 days (IQR = 2.75-5.75 days), representing 5% of all patients receiving continuous RRT in our hospital during 2015. Five patients (3%) died during the AKI episode hospital admission.
Recognition
Acute kidney injury was identified in the PED in 46 to 239 (19%) of patient encounters (Table 2) and by an inpatient team in 123 of 199 (62%) encounters; in 74 of 199 (37%) of encounters of children admitted to an inpatient unit, AKI was not recognized by a PED nor inpatient clinician. After hospital admission, AKI was more likely to be diagnosed in patient encounters admitted to medical teams (119/186, 64%) than surgical teams (4/13, 31%; OR = 4.0, 95% CI = 1.19-13.5) ( Table 3) .
Patient encounters recognized by PED clinicians as having AKI (Table 3) were older (13 years old vs. 10 years old, p = 0.0114), had more severe (Stage 2 or 3) AKI (OR = 5.5, 95% CI = 2.6-11.8), and were more likely to be admitted (OR = 10.3, 95% CI = 1.38-77.4) than encounters in whom AKI was not diagnosed in the PED. There was no statistical difference in AKI detection based on underlying comorbidities or presentation to the quaternary care versus community-based PED. There was no statistically significant difference in LOS (6.5 days vs. 5 days, p = 0.39), need for RRT (OR = 1.25, 95% CI = 0.13-12.4), or mortality (p = 0.59) in those diagnosed with AKI versus those missed. Three of four patients progressing to need RRT were not diagnosed with CA-AKI by a PED clinician. Differences in population proportions for the outcomes are listed in a supplemental table (Data Supplement S2, Table S3 ).
On additional analysis, PED clinicians were concerned with renal function but did not formally Data re reported as n (%) or median (IQR). AKI = acute kidney injury; CRRT = continuous renal replacement therapy; IQR = interquartile range; PED = pediatric emergency department; pts = patients. *Details regarding patient percentages will not add up to 100% as some patients had multiple encounters and fell into multiple categories during different encounters. †Two patients (three encounters) were transferred to another hospital and their inpatient data could not be evaluated. Inpatient data is from 186 patients (199 encounters) admitted. ‡Comorbidities of patients and encounters do not add up to 100% as some patients/encounters had multiple comorbidities; 131 patients/ 154 encounters had one or more comorbidities; and 85 patients/85 encounters had no comorbidity. §Medical team includes critical care team as all patients admitted to an intensive care unit in this cohort of patients were nonsurgical.
diagnose AKI in an additional 73 encounters; therefore, with the expanded search, clinicians were renal conscious in 50% (119/239) of AKI encounters (Data Supplement S2, Table S4 ). The encounters in which the PED clinicians were renal conscious (Table S4) had longer hospital LOS (6 days vs 4 days, p = 0.027) when compared to encounters that did not document concern for renal function nor diagnose AKI. In multivariable analysis (Table 4) , stage 2 or 3 AKI was independently associated with AKI diagnosis in the PED when controlled for sex, age, AKI stage, and presence of comorbidity.
Age-based Creatinine Ranges AKI was not diagnosed by the ED clinicians in any encounter if the creatinine was not flagged as abnormal by the laboratory, regardless of patient age or creatinine level. All 46 AKI encounters identified by PED clinicians had creatinine levels flagged as abnormal (Table 3) . Almost one-third (74/239) of encounters with AKI would have never been flagged as elevated creatinine by the laboratory as their peak creatinine fell below the laboratory upper limit of normal (1.06 mg/ dL). Admitted to a surgical team (n = 13) 4 (31) 9 (69)
A total of 239 encounters with AKI seen in ED. Of those, 202 encounters were admitted; however, inpatient data for only 199 encounters are available as three encounters (two patients) were transferred to another hospital. Children transferred to other hospitals were not included in LOS, *Data are reported as n (%). †Data are reported as n (%) of encounters. RRT, mortality data, nor in calculations of AKI recognition inpatient. AKI = acute kidney injury; CA-AKI= community-acquired AKI; IQR = interquartile range; LOS = length of stay; RRT = renal replacement therapy.
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Putative Etiologies for AKI Infections were most commonly associated with AKI based on PED diagnoses, followed by prerenal etiologies (gastrointestinal disorders, vomiting, and diarrhea; Data Supplement S1, Figure S2 ). Primary renal disorders, such as glomerulonephritis, were next most common.
Use of Potentially Nephrotoxic Medications
Twenty-five percent (60/239) of all patient encounters with AKI received nephrotoxic interventions (Table 2) , most commonly antimicrobials (Figure 1 ). There was no statistically significant difference in nephrotoxic therapy use comparing encounters with diagnosed AKI versus missed AKI (OR = 0.57, 95% CI = 0.25-1.3; Table 3 ). However, on additional analysis clinicians used less nephrotoxic interventions in the renal conscious group compared to the encounters that documented no concern for renal function (OR = 0.53, 95% CI = 0.3-0.98; Table S4 ).
DISCUSSION
With very few studies in the literature specifically evaluating pediatric CA-AKI, we provided a broad description of CA-AKI seen in a PED. Our CA-AKI incidence was higher than that in the few other studies evaluating CA-AKI. [19] [20] [21] More importantly, we highlighted the poor recognition of AKI. We propose that using age-based creatinine ranges will improve clinician recognition of AKI and potentially improve resource utilization, morbidity, and mortality among children with CA-AKI.
Our incidence of CA-AKI is higher than that previously reported in the literature. Environmental differences, differences in the definitions of AKI used, and differences in the baseline creatinine measurement may account for the discrepancy. The use of age-based creatinine ranges allowed us to detect AKI in an additional 161 encounters that did not have personal baseline creatinine levels, which may account for the increased incidence in our population.
In our study, PED clinicians recognized AKI in 19% of encounters, an incidence of 0.3%. This incidence is very similar to that in the literature examining administrative data for AKI recognition using ICD-9 or ICD-10 codes. 22, 23 The discrepancy between AKI studies using diagnosis codes versus using structured definitions of AKI highlights the underrepresentation of the true incidence of AKI in EHRs. 44 The underrecognition and diagnosis of AKI in the PED specifically may be due to the lack of individual baseline creatinine values or UOP documentation to properly assess for AKI, as a recent international multicenter study reported that 20% of AKI cases could only be diagnosed based on UOP criteria. 16 Alternatively, it might be reflective of the relative unfamiliarity of the PED clinicians with current AKI definitions and reliance on laboratory notifications for abnormal creatinine levels. Although there has been an increasing number of studies on HA-AKI, the majority of this knowledge is disseminated in critical care and nephrology journals that PED physicians might not frequently read. Comparing patient encounters with AKI that were identified to those in whom AKI was missed, patients identified were older, had higher creatinine levels, and had more severe AKI (stage 2 or 3). There were no differences in comorbidities, indicating no specific medical condition that would lead clinicians to better recognize AKI. This may be due to the low prevalence of chronic medical conditions in children.
Clinicians did recognize that patients with AKI had higher severity of illness needing further inpatient management, as all but one child with recognized AKI was admitted, an admission rate fivefold higher than that of the general PED population. Patients did receive fewer nephrotoxic interventions during encounters in which clinicians were renal conscious (documented as concern for renal function in the EHR or formally given the diagnosis of AKI) and they also had longer hospital stays. Although the five patients in this study who died during this hospital admission were in the undiagnosed group, it is difficult to determine if CA-AKI contributed to their deaths, if nephrotoxic therapy exposure while inpatient increased their risk of mortality, or if their mortality simply reflected the severity of their underlying disease.
Reporting AKI is a challenge in pediatrics as it involves knowing a patient's baseline creatinine, UOP, height, and weight. Traditionally, AKI is diagnosed as a 1.5-fold increase relative to a patient's personal baseline creatinine, often described in pediatrics as the patient's lowest creatinine value in the previous 3 months, accounting for creatinine changes with growth. Lack of a baseline creatinine hinders a physician's ability to determine if a patient has AKI. In addition, the use of one wide normal creatinine range, such as in adult medicine, does not reflect the physiologic changes in creatinine with growth and does not alert clinicians to abnormal values in the pediatric population. We created age-based creatinine ranges and validated them using a population-based study with values reflecting the normal creatinine ranges of the children seen in our PED. During the study period, the laboratory still reported one wide normal creatinine range for all pediatric patients, potentially contributing to the high number of missed AKI encounters by our PED clinicians. The new age-based creatinine ranges would flag as high when creatinine rises above 0.4 mg/dL in younger children, alerting clinicians to fivefold as many abnormal values in this study.
Still, reliance on a personal baseline for determining relative increases in creatinine for AKI diagnosis is problematic in the PED, where only a minority of patients had chronic comorbidities and therefore have previous creatinine levels in the EHR. Using age-based normal creatinine ranges allowed us to evaluate for AKI in all patients with a serum creatinine collected when only 33% of these patients in our cohort had a personal baseline. In addition, most of these encounters with a personal baseline level met AKI both by using their baseline creatinine and by using the agebased range. Since this study, these age-based creatinine ranges have been incorporated into our EHR, warning clinicians when abnormal and potentially alerting them to AKI sooner in the fast-paced acute care setting. Given the success of previous studies, we further plan to create an EHR alert to detect changes in creatinine levels and warn clinicians to development of AKI in their patients. 39 Resource utilization was high in pediatric CA-AKI, with most patients admitted to the hospital and almost half needing critical care services. It is difficult to determine if hospital admission was most likely related to overall severity of illness of the patient and how strongly CA-AKI contributed. A small portion of patient encounters went on to need RRT. It is impossible to determine whether earlier identification would have decreased the RRT requirement or if the need for RRT was a reflection of their disease process; however, earlier identification of AKI patients would facilitate nephrology involvement from admission as delayed nephrology consultation has been reported to be associated with increased mortality, higher dialysis dependence, and longer LOS. [34] [35] [36] 
LIMITATIONS
Our incidence of CA-AKI was low, which could affect the precision of the results. Only a minority of children had creatinine measured in the PED encounter, which could have led to a falsely low incidence of CA-AKI. There were multiple limitations as a chart review. 45 Trying to discern the degree of concern for AKI was challenging using the EHR and the primary medical record data abstractor was not blinded to the study, which could introduce bias. The trained data abstractor completed a limited number of practice charts and was only able to review 10% of the EHR data, which may not have been adequate. Ambiguous data were flagged and then discussed in person with the primary investigator, which could have introduced bias. By using classification codes and diagnoses, we may have underestimated ED clinician's recognition of AKI, leading to classification bias. We were also unable to determine if clinicians were concerned about renal function prior to administration of nephrotoxic medications, potentially changing their prescribing practice. As a resource-abundant single-center study, not all results may be generalizable. Using the creatinine KDIGO AKI criteria and excluding the UOP metric might have underreported the true frequency of AKI. Finally, we have not tested if using age-specific creatinine ranges leads to higher or lower false positives than using a patient's own baseline creatinine and this validation study is ongoing and will be reported in future studies.
CONCLUSIONS
Community-acquired acute kidney injury remains an under-recognized entity in the pediatric ED. Our incidence was higher than that in other studies that evaluated community-acquired acute kidney injury with higher rates of hospitalization. We did not find any patient characteristics that would help pediatric ED clinicians better identify acute kidney injury. Age-based creatinine ranges that reflect the physiologic changes of creatinine with growth helped determine acute kidney injury in all patients, including those without personal baseline creatinine levels. Better tools to recognize acute kidney injury in the busy pediatric ED environment are needed. Our next step is to improve detection of acute kidney injury through the creation of an electronic alert that will automatically notify a provider in real time when a child meets acute kidney injury criteria.
